LifeMD 

LifeMD, Inc. is a telehealth company, which engages in offering portfolio of direct-to-patient products and services. It combines virtual medical treatment with prescription medications and over-the-counter products. The firm's network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the United States. The firm's brands include Shapiro, Rex, and Nava. The company was founded in 1987 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AGF Management reports stable performance and growth opportunities in Q1 2023

AGF Management delivered stable performance in Q1 2023 with positive net sales and a dividend increase.
While facing challenges in certain business segments, AGF's strong cash position and investment portfolio provide a solid foundation.
Opportunities lie in capital allocation strategies, growth initiatives, and enhancing performance in key business areas.
Overall, AGF's focus on shareholder returns and strategic investments positions the company for future growth and success.

LifeMD surpasses Q1 expectations, eyes growth amid challenges

LifeMD's Q1 2023 performance exceeded expectations, driven by strong revenue and EBITDA results.
The company's strategic initiatives, including debt financing and AI integration, position it for growth.
Challenges lie in maintaining growth momentum, managing costs, and optimizing EBITDA margins.
Opportunities in partnerships, telehealth, and patient value enhancement offer avenues for future growth.

LifeMD reports strong Q2 performance and raises revenue guidance

LifeMD's Q2 performance reflects operational strength, revenue growth, and strategic initiatives driving positive results and financial stability.
While facing challenges in adjusted EBITDA guidance due to investments, the company maintains a strong position with record revenues and subscriber growth.
Opportunities for growth and expansion exist through the weight management program, partnerships, and focus on existing health care businesses.

LifeMD reports record Q3 revenue and profitability, eyes growth opportunities

LifeMD's Q3 results reflect a successful quarter marked by strong revenue, profitability, and subscriber growth. The company's focus on strategic initiatives and positive outlook for 2024 indicate a promising future with plans to accelerate momentum and deliver impressive results.

LifeMD reports record 2023 performance, eyes growth in weight management

LifeMD's strong performance in 2023 sets the stage for continued growth and profitability. The company's strategic focus on diversification, market expansion, and cost management positions it well for future success. Challenges in subscriber numbers and commercial partnerships require attention, but overall, LifeMD is on a positive trajectory.

LifeMD excels in Q2 with telehealth growth, WorkSimpli rebounds

LifeMD demonstrated robust performance in Q2 2024, driven by the success of its core telehealth business and strategic initiatives.
While facing challenges, WorkSimpli is making progress towards regaining peak profitability by addressing competitive and executional issues.
Opportunities lie in expanding service offerings, enhancing collaborations, and leveraging upcoming launches to drive growth and profitability for LifeMD.
Strategic focus on innovation, efficiency, and market differentiation positions LifeMD well for sustained success and revenue growth in the future.

LifeMD reports robust Q3 results, eyes Medicare expansion for growth

LifeMD's Q3 performance reflects strong revenue growth, operational improvements, and strategic expansion initiatives.
The company's focus on telehealth, men's health, and work simplification businesses is driving positive results.
While facing challenges in scaling operations and market competition, LifeMD is well-positioned for continued growth.
Opportunities in Medicare expansion, program enhancements, and market partnerships offer avenues for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

NEW YORK, May 25, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD) and certain of its officers.   The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-04004, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired LifeMD securities between January 19, 2021 and April 13, 2021, inclusive (the "Class Period").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in LifeMD, Inc. f/k/a Conversion Labs, Inc. of Class Action Lawsuit and Upcoming Deadline - LFMD

SAN DIEGO--(BUSINESS WIRE)-- #LFMDstock--The suit alleges defendants issued false statements concerning LifeMD business and prospects, resulting in its stock trading at inflated prices.

CORRECTING and REPLACING Robbins Geller Rudman & Dowd LLP Announces Lead Plaintiff Deadline in the LifeMD, Inc. Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP Announces Lead Plaintiff Deadline in the LifeMD, Inc. Class Action Lawsuit

The partnerships introduce celebrity influencers and their successful results using Shapiro MD™ hair loss treatment solutions to a large and global following The partnerships introduce celebrity influencers and their successful results using Shapiro MD™ hair loss treatment solutions to a large and global following

Star Actresses Kate del Castillo and Bellamy Young Partner With LifeMD as Brand Ambassadors For Shapiro MD

NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that the Compensation Committee of the Company's Board of Directors granted an equity award to a new employee.  The equity award was an inducement material to the employee's acceptance of employment with the Company. The award was granted outside of the Company's 2020 Equity and Incentive Plan (but consistent with its terms) and approved on May 17, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

LifeMD™ Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The stock price of LifeMD Inc (NASDAQ: LFMD) increased by over 24% during intraday trading. This is why it happened.

LifeMD (LFMD) Stock: Over 24% Increase Explanation

LifeMD Inc (NASDAQ: LFMD) reported Q1 adjusted EPS loss of $(0.38) better than the consensus loss of $(0.67). Revenue increased 323% Y/Y to a record $18.2 million in line with the consensus, primarily driven by a 349% increase in telemedicine product revenues.

LifeMD Shares Shoot Higher On Robust Q1 Telemedicine Revenues, FY Revenue Outlook Exceeding Consensus

LifeMD, Inc. (LFMD) CEO Justin Schreiber on Q1 2021 Results - Earnings Call Transcript

LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 13.64% and -0.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. (LFMD) Reports Q1 Loss, Lags Revenue Estimates

NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today reported results for the first quarter ended March 31, 2021. All quarterly comparisons are to the same year-ago period. The Company will hold a conference call at 4:30 p.m. Eastern time today to discuss the results (see dial-in information below.)

LifeMD Reports Q1 2021 Revenue up 323% to Record $18.2M, Raises Full Year Revenue Guidance to $90-$100M

LOS ANGELES, May 13, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  June 15, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD) securities between January 19, 2021 and April 13, 2021 , inclusive (the "Class Period"). If you suffered a loss on your LifeMD investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/lifemd-inc/.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against LifeMD, Inc. (LFMD)

Investors need to pay close attention to LifeMD (LFMD) stock based on the movements in the options market lately.

Do Options Traders Know Something About LifeMD (LFMD) Stock We Don't?

LifeMD, Inc. (LFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate LifeMD, Inc. (LFMD) to Report a Decline in Earnings: What to Look Out for

SAN DIEGO & NEW YORK--(BUSINESS WIRE)---- $LFMD #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of LifeMD f/k/a Conversion Labs, Inc. (NASDAQ: LFMD) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between January 19, 2021 and April 13, 2021. LifeMD is direct-to-patient telehealth company that purports to help patients access licensed providers for diagnose, virtual care, and prescri

SHAREHOLDER ALERT: Robbins LLP Reminds Investors That LifeMD, Inc. (LFMD) f/k/a Conversion Labs, Inc. (CVLB) is Being Sued for Misleading Shareholders

NEW YORK, May 5, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. f/k/a Conversion Labs, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-04004, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired LifeMD securities between January 19, 2021 and April 13, 2021, inclusive (the "Class Period").

Pomerantz Law Firm Announces the Filing of a Class Action Against LifeMD, Inc. f/k/a Conversion Labs, Inc. and Certain Officers - LFMD

Los Angeles, May 4, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD) securities between January 19, 2021 and April 13, 2021 , inclusive (the "Class Period").

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of LifeMD, Inc. (LFMD) Investors

New York, New York--(Newsfile Corp. - April 30, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired LifeMD securities between January 19, 2021 and April 13, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the...

LFMD Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds LifeMD, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

NEW YORK, April 23, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased LifeMD, Inc. (NASDAQ: LFMD) securities between January 19, 2021 and April 13, 2021, inclusive (the "Class Period"). All investors who purchased shares of LifeMD, Inc. and incurred losses are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

LIFEMD, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against LifeMD, Inc.

SAN DIEGO & NEW YORK--(BUSINESS WIRE)---- $LFMD #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of LifeMD f/k/a Conversion Labs, Inc. (NASDAQ: LFMD) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between January 19, 2021 and April 13, 2021. LifeMD is direct-to-patient telehealth company that purports to help patients access licensed providers for diagnoses, virtual care, and prescription m

SHAREHOLDER ALERT: Robbins LLP Announces That LifeMD, Inc. (LFMD) f/k/a Conversion Labs, Inc. (CVLB) is Being Sued for Misleading Shareholders

New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether LifeMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeMD, Inc. - LFMD

BENSALEM, Pa.--(BUSINESS WIRE)---- $LFMD #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming June 15, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) securities between January 19, 2021 and April 13, 2021, inclusive (the “Class Period”). Investors suffering losses on their LifeMD investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against LifeMD, Inc. (LFMD)

Notice of Lead Plaintiff Deadline for Shareholders in the LifeMD Class Action Lawsuit

Boston, Massachusetts--(Newsfile Corp. - April 20, 2021) -  The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of LifeMD, Inc. (NASDAQ: LFMD). The case is currently in the lead plaintiff stage. Investors who purchased LFMD stock or other securities between January 19, 2021 and April 13, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/LifeMD to submit their information. Investors may also...

LifeMD Investor Alert: Shareholder Lawsuit Filed

NEW YORK, April 20, 2021 /PRNewswire/ -- Attorney Advertising - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired LifeMD securities between January 19, 2021 and April 13, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/lfmd.

LFMD Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies LifeMD, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased LifeMD, Inc. (NASDAQ: LFMD) securities between January 19, 2021 and April 13, 2021, inclusive (the “Class Period”). Investors have until June 15, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit

LIFEMD ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against LifeMD, Inc. and Encourages Investors to Contact the Firm

News for LifeMD Stock (LFMD)